See the DrugPatentWatch profile for wegovy
Wegovy was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021 [1].
What is Wegovy used for?
Wegovy (semaglutide) is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia, when used in conjunction with a reduced-calorie diet and increased physical activity [1].
How does Wegovy work?
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist [1]. It mimics the action of the GLP-1 hormone, which helps regulate appetite and food intake. By activating GLP-1 receptors in the brain, it can reduce hunger and increase feelings of fullness, leading to decreased calorie consumption [1].
How does Wegovy compare to other weight loss medications?
Wegovy is a prescription medication that works similarly to other GLP-1 receptor agonists, such as Ozempic (also semaglutide) and Saxenda (liraglutide), which are also used for weight management. Clinical trials have shown significant weight loss in participants using Wegovy compared to placebo [1].
What are the potential side effects of Wegovy?
Common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, and abdominal pain [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, and thyroid tumors [1].
When does Wegovy's patent expire?
Information on the specific patent expiry dates for Wegovy is available through specialized patent tracking resources [2]. DrugPatentWatch.com tracks patent information for many pharmaceutical products.
Who manufactures Wegovy?
Wegovy is manufactured by Novo Nordisk [1].
What is the clinical data supporting Wegovy's approval?
The FDA approval of Wegovy was based on data from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. The STEP 8 trial, a pivotal study, demonstrated that adults with overweight or obesity who received 2.4 mg of semaglutide once weekly achieved a mean weight reduction of 12.7% from baseline compared to 2.4% with placebo over 68 weeks [1].
Can Wegovy be used for diabetes management?
While Wegovy (semaglutide) is approved for chronic weight management, semaglutide is also available under the brand name Ozempic, which is approved for improving glycemic control in adults with type 2 diabetes mellitus [1].
---
Sources:
[1] https://www.wegovy.com/
[2] https://drugpatentwatch.com/